EPAS1 and nonpapillary renal cell carcinoma: For patients with metastatic ccRCC, approved therapies include cytokine therapy, tyrosine kinase inhibitors (TKIs), HIF2a inhibitors, anti-angiogenesis agents and immune checkpoint blockade (18, 19).